AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17950677
Drug: AZD0865 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0865 75 mg
Trial: 10343145
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy regimen of pantoprazole 40 mg (twice daily), clarithromycin 500 mg, and amoxicillin 1,000 mg for 1 week
Trial: 10343145
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy regimen of pantoprazole, clarithromycin, and amoxicillin
Trial: 6351517
Drug: Varidase solution
RxNorm normalized name: DIMETHICONE 30 mg in 1 mL TOPICAL CREAM [AnYi Beauty Varicose Veins Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varidase solution
Trial: 31987919
Drug: Add-on strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on strategies (lithium, lamotrigine/carbamazepine, anti-inflammatory drugs)
Trial: 15842558
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg tolterodine bid
Trial: 15842558
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oxybutynin tid
Trial: 12554247
Drug: Misoprostol 50
RxNorm normalized name: diclofenac-misoprostol 50 mg-200 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 50 microg (low dose)
Trial: 12554247
Drug: Misoprostol 100
RxNorm normalized name: MISOPROSTOL 100MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 100 microg (high dose)
Trial: 2132187
Drug: Transfer from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer from porcine to human insulin
Trial: 2132187
Drug: Transfer from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer from bovine to human insulin
Trial: 31642244
Drug: Individualized intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized intervention through the combination of prenatal and postnatal care
Trial: 28537012
Drug: Nutraceutical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical treatment
Trial: 23391196
Drug: Both Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Both Rivaroxaban and Warfarin
Trial: 19656250
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion (20 mg ATP during isoproterenol infusion)
Trial: 8794413
Drug: Ifosfamide 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 2.0 g/m2 days 1-3, mesna 400 mg/m2 at 0, 4, 6 h days 1-3, cisplatin 33 mg/m2 days 1-3 with G-CSF 5 micrograms/kg SQ day 4 to post day 11.
Trial: 8794413
Drug: Etoposide 200
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 200 mg/m2 days 1-3, cisplatin 35 mg/m2 days 1-3 with G-CSF 5 micrograms/kg SQ day 4 to post day 11.
Trial: 2297966
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection (mean 0.975 ml/s)
Trial: 2297966
Drug: Rapid injection
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid injection (mean 2.575 ml/s)
Trial: 7270561
Drug: Timolol maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol maleate 10 mg and hydrochlorothiazide 25 mg (T/H)
Trial: 7270561
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg (HCTZ)
Trial: 28494595
Drug: G‐Coat Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐Coat Plus
Trial: 28494595
Drug: Both G‐Coat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both G‐Coat Plus and Heliobond
Trial: 21068008
Drug: L-4F administered
RxNorm normalized name: 4F-PCC
DrugBank: Factor IX Complex (Human) (DB11330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-4F administered by intravenous (IV) infusion for 7 days
Trial: 21068008
Drug: L-4F administered
RxNorm normalized name: 4F-PCC
DrugBank: Factor IX Complex (Human) (DB11330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-4F administered by subcutaneous (SC) injection for 28 days
Trial: 21068008
Drug: L-4F at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-4F at concentrations of 150, 375, or 1,000 ng/ml added to plasma ex vivo
Trial: 11441198
Drug: Enalapril at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril at 10 mg/d (n=48)
Trial: 8883531
Drug: iodixanol at
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iodixanol at 270 mg I/ml (IOD-270)
Trial: 8883531
Drug: iohexol at
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iohexol at 300 mg I/ml (IOH-300)
Trial: 1562096
Drug: Atropine 0.01
RxNorm normalized name: atropine 0.0194 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.01 mg/kg i.v. 10 min prior to intubation
Trial: 1562096
Drug: Atropine 0.01
RxNorm normalized name: atropine 0.0194 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.01 mg/kg i.m. 30 min prior to intubation
Trial: 4056240
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of hydrocortisone (300 mg)
Trial: 4056240
Drug: Intravenous injections
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injections of 20 mg of methylprednisolone, 4 mg of dexamethasone, or 4 mg of betamethasone
Trial: 22734581
Drug: Paracetamol i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol i.v. 1 g
Trial: 22734581
Drug: Paracetamol i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol i.v. 2 g
Trial: 22734581
Drug: Oxycodone i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone i.v. (0.1 mg/kg)
Trial: 19841862
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) for 6 weeks
Trial: 2013244
Drug: Metronidazole 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 0.5 g plus amikacin 500 mg i.v. 2 h before surgery and the same doses per 8 or 12 h for 2 days postoperatively (Group A)
Trial: 2013244
Drug: Ornidazole 1
RxNorm normalized name: ornidazole 167 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornidazole 1 g by intravenous infusion plus ceftriaxone 2 g i.v. 2 h before surgery and the same doses per 24 h for 2 days postoperatively (Group B)
Trial: 24723147
Drug: Rivastigmine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (mean dose 5.1 ± 2.3 mg/day)
Trial: 22287221
Drug: Two 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 8 Gy doses of external beam radiation
Trial: 20481041
Drug: Imunofan combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imunofan combined with basic therapy
Trial: 15012924
Drug: 3-month aerobic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month aerobic program above standard treatment
Trial: 15012924
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without special advice for exercise
Trial: 11603100
Drug: Keto acids/amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keto acids/amino acids (KA) supplementation at a dosage of 100 mg/kg/day
Trial: 9587722
Drug: Bupivacaine-Midazolam (0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine-Midazolam (0.125% bupivacaine 0.75 mL kg‐1 with 0.5% midazolam 50 micrograms kg‐1)
Trial: 9587722
Drug: Bupivacaine-Morphine (0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine-Morphine (0.125% bupivacaine 0.75 mL kg‐1 with 1% morphine chlorhydrate 0.05 mg kg‐1)
Trial: 9587722
Drug: Bupivacaine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine alone (0.125% bupivacaine 0.75 mL kg‐1)
Trial: 31004523
Drug: Oral function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral function intervention only
Trial: 31004523
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral function plus nutritional intervention
Trial: 28993388
Drug: Basic medication
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic medication reminder app group
Trial: 28993388
Drug: Advanced medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced medication reminder app group
Trial: 25778987
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of American ginseng (Panax quinquefolius)
Trial: 2130002
Drug: Ceftriaxone 60-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 60-80 mg/kg/day intramuscularly for 5-7 days
Trial: 2130002
Drug: Chloramphenicol 50-80
RxNorm normalized name: chloramphenicol 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol 50-80 mg/kg/day orally in 4 divided doses for 12-14 days
Trial: 371646
Drug: Intravenous mexiletine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous mexiletine (150 mg bolus injection)
Trial: 31535807
Drug: SpermActin Forte,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SpermActin Forte, 1 sachet of 10 g once a day for 180 days
Trial: 29217455
Drug: Monovision contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovision contact lenses without far prescription
Trial: 26433727
Drug: Rapid clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rapid clozapine titration (started at 25-50 mg, increased by 50-100 mg/day)
Trial: 26433727
Drug: Slow clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slow clozapine titration (started at 12.5-50 mg, increased by 25-50 mg/day)
Trial: 26433727
Drug: Rapid clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rapid clozapine titration
Trial: 26433727
Drug: Slow clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slow clozapine titration
Trial: 24673714
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (SD) of enteric-coated mycophenolate sodium (1440 mg/day)
Trial: 24673714
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (LD) of enteric-coated mycophenolate sodium (1080 mg/day)
Trial: 24673714
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (SD) of enteric-coated mycophenolate sodium
Trial: 24673714
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (LD) of enteric-coated mycophenolate sodium
Trial: 22530305
Drug: Ibandronate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (30 mg) with SNAC (1:5 ratio)
Trial: 22530305
Drug: Ibandronate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (30 mg) with SNAC (1:10 ratio)
Trial: 22530305
Drug: Ibandronate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (30 mg) with SNAC (1:20 ratio)
Trial: 22530305
Drug: Approved oral
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Approved oral Ibandronate tablet formulations (150 mg IBN)
Trial: 22530305
Drug: Increasing post-dose
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing post-dose fasting duration from 15 to 30 min
Trial: 22530305
Drug: IBN/SNAC treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBN/SNAC treatments
Trial: 15752384
Drug: Paracetamol 4
RxNorm normalized name: Paracetamol 48.2 mg/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 4 g day(-1)
Trial: 2258297
Drug: Interferon Alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon Alfa‐2b (Intron A) administered at a low-dose regimen (1 million I.U. s.c. daily for 6 days with a 2-week interval between courses)
Trial: 6786074
Drug: Cysteine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteine supplementation (77 mg/kg/24 h)
Trial: 6786074
Drug: Control intravenous
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control intravenous formulations
Trial: 29679529
Drug: Parenteral ω‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral ω‐3 LC‐PUFAs (EPA and DHA)
Trial: 29679529
Drug: None of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: None of the parenteral lipid emulsions
Trial: 25039675
Drug: Exenatide vs
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide vs Insulin
Trial: 19009634
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 2.0-2.5 mg/kg a day
Trial: 19009634
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) 6-9 mg a day
Trial: 18812202
Drug: pTHr.HIVA DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pTHr.HIVA DNA vaccine (0.5 mg or 2 mg) followed by MVA.HIVA (5 x 10^7) at weeks 8 and 12 (early boost) or weeks 20 and 24 (late boost)
Trial: 18812202
Drug: pTHr.HIVA DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pTHr.HIVA DNA vaccine (0.5 mg or 2 mg) followed by MVA.HIVA (5 x 10^7)
Trial: 28146560
Drug: Weekly drink
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly drink self-tracking mobile assessment texts (MA)
Trial: 26201694
Drug: 0.1 g/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 g/kg/h of glucose
Trial: 23958074
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg of oral T3 every 12 hours starting 20 minutes before anesthetic induction, for a total of 4 doses
Trial: 19190958
Drug: Fluoxetine (20mg)
RxNorm normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20mg)
Trial: 17141739
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 IU Syntocinon)
Trial: 8153781
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of ketorolac orally
Trial: 8153781
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of morphine intramuscularly
Trial: 8153781
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of morphine intramuscularly
Trial: 27548886
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg CoQ10 supplementation for 12 weeks
Trial: 27548886
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg CoQ10 supplementation for 12 weeks
Trial: 14573316
Drug: Hydrocortisone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (100 mg orally)
Trial: 8476616
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg/kg added to axillary block solution (AX)
Trial: 8476616
Drug: Saline added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline added to axillary block solution with morphine 0.1 mg/kg IV (CT)
Trial: 3090830
Drug: High-dose cytosine
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytosine arabinoside (HIDARAC)
Trial: 16157900
Drug: Mitoxantrone 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 12 mg/m2
Trial: 16157900
Drug: Mitoxantrone 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 5 mg/m2
Trial: 10953829
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (omeprazole, tetracycline, metronidazole, bismuth subcitrate) for 7 days followed by OCA7 if failure
Trial: 10953829
Drug: OCA7 for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA7 for 7 days followed by quadruple therapy if failure
Trial: 6392353
Drug: Intramuscular levonantradol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular levonantradol 0.5 mg
Trial: 6392353
Drug: Intramuscular levonantradol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular levonantradol 1.0 mg
Trial: 6392353
Drug: Intramuscular levonantradol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular levonantradol 1.5 mg
Trial: 6392353
Drug: Intramuscular levonantradol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular levonantradol 2.0 mg
Trial: 31059641
Drug: HTTRx (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTTRx (10 mg)
Trial: 31059641
Drug: HTTRx (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTTRx (30 mg)
Trial: 31059641
Drug: HTTRx (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTTRx (60 mg)
Trial: 31059641
Drug: HTTRx (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTTRx (90 mg)
Trial: 31059641
Drug: HTTRx (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTTRx (120 mg)
Trial: 28578601
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (single-agent chemotherapy of physician's choice)
Trial: 25835109
Drug: 5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 µg ramosetron
Trial: 17129592
Drug: Royal Drug
RxNorm normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Royal Drug albendazole
Trial: 14695734
Drug: Oral amantadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amantadine
Trial: 15892278
Drug: Gufusheng capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gufusheng capsule (GFSC) combined with arthrectomy hip synovial membrane excision, femoral head decompression, and muscle-bone flap transplantation
Trial: 8598699
Drug: Continued second-line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued second-line therapy (n = 142)
Trial: 1662127
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 300 mg on the first day and 150 mg for the subsequent 5 days (Group 1)
Trial: 1662127
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 400 mg on the first day and 200 mg for the subsequent 5 days (Group 2)
Trial: 6123123
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg cloxazolam
Trial: 29645317
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion (SI) of low-dose ketamine (0.3 mg/kg)
Trial: 29645317
Drug: Intravenous push
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous push (IVP) of low-dose ketamine (0.3 mg/kg)
Trial: 24213962
Drug: High-intensity blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity blue light therapy (λmax = 465 nm, 84.8 µW/cm(2), 39.5 lux, 1.74 × 10(14) photons/cm(2)/s)
Trial: 24213962
Drug: Lower-intensity yellow
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-intensity yellow light therapy (λmax = 574 nm, 18.5 µW/cm(2), 68 lux, 1.21 × 10(12) photons/cm(2)/s)
Trial: 22947842
Drug: Complete oral
RxNorm normalized name: Canker Complete Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete oral prophylaxis (periodontal therapy)
Trial: 16291984
Drug: Sildenafil (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (one year treatment)
Trial: 11889322
Drug: GIK solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK solution (30% glucose in water with insulin 50 IU/L, and KCl 40 mM) at 1.5 mL/kg/hr for 24 hrs
Trial: 11889322
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) at 1.5 mL/kg/hr for 24 hrs
Trial: 21591581
Drug: G-CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (10 microg/kg body weight) for five consecutive days
Trial: 15731121
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.03%
Trial: 19922703
Drug: Topical pimecrolimus
RxNorm normalized name: pimecrolimus Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pimecrolimus
Trial: 15731121
Drug: Topical pimecrolimus
RxNorm normalized name: pimecrolimus Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pimecrolimus and tacrolimus
Trial: 12018715
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (1 g IV for 3 days in weeks 1 and 2, 2 days in week 3, 1 day in week 4)